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SUMMARY 
Background: Pharmacogenetics has a potential for 
optimizing drug response and identifying risk of tox-
icity for patients. Pharmacogenetics knowledge of 
healthcare professionals and the unmet need for 
pharmacogenetics education in health training institu-
tions are some of the challenges of integrating phar-
macogenetics into routine medical practice.  
Aim: To assess pharmacogenetics knowledge among 
healthcare professionals and faculty members of 
health training institutions in Ghana.  
Method: Semi-structured questionnaires were used 
to interview healthcare professionals from selected 
public and private hospitals. Faculty members from 
health training institutions were also interviewed.  
Results: The respondents were Medical doctors 42 
(46.7%), Pharmacists 29 (32.2%) and Nurses 19 
(21.1%). Healthcare professionals rated their 
knowledge of Pharmacogenetics as Excellent 5 
(5.6%), Very Good 10 (11.2%), Good 53 (60%) and 
Poor 19 (21.4%). Thirty-two faculty members from 
health training institutions were also interviewed. 
Faculty members rated their knowledge of phar-
macogenetics as Excellent 2 (6.3%), Very Good 3 
(9.4%), Good 9 (28.1%), Fair 12 (37.5%) and Poor 6 
(18.8%). Thirty seven percent (12) of these faculty 
members said pharmacogenetics was not part of their 
institutions’ curriculum, 7 (22%) did not know if 
pharmacogenetics was part of their curriculum and 
only 13 (40.6%) said it was part of their curriculum.  
Conclusion: Few healthcare professionals and facul-
ty members of training institutions are aware of the 
discipline of pharmacogenetics. There is the need for 
continuous professional education on pharmaco-
genetics and development of competency standards 
for all healthcare professionals in Ghana. 
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INTRODUCTION 
There has been considerable scientific, corporate and 
policy interest in the more effective use of genetics in 
both drug development and delivery in the world.1 
Available literature has documented variations in drug 
response among individuals leading to differences in the 
extent of adverse drug reactions as well as efficacy of 
drug treatment.2 
 
The genetic make-up of the individual, in addition to 
both the physiological and environmental factors, have 
had a profound impact on individual’s response to medi-
cations. Pharmacogenetics has been defined as the effect 
of genetic variation on drug response while Phar-
macogenomics encompasses all genes in the genome that 
may determine drug response.3 Pharmacogenetics and 
Pharmacogenomics is being used interchangeably and is 
a new field which has potentially made it possible for the 
identification of individuals in whom a particular treat-
ment will be effective or select those individuals who 
will have an increased chance of life threatening adverse 
reaction to a particular medication.4  
 
Although pharmacogenetics testing is currently available 
only to a small number of patients, it is likely to influ-
ence clinical practice to a larger extent in the near fu-
ture.5 Pharmacogenetics will serve to improve individual 
country’s “ability to respond to local disease threats” and 
to “make better policy decisions regarding the most op-
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The Food and Drug Administration of the United 
States of America (US-FDA) requires inclusion of 
pharmacogenetics information in over 100 drug la-
bels, which is approximately 10% of all drug labels 
up to 2005.7 It is therefore important that all 
healthcare professionals (Doctors, Pharmacist, Physi-
cian Assistants and Nurses) in all areas where phar-
macogenetics testing or information will be available 
are familiar with the knowledge to be able to interpret 
and sufficiently explain and incorporate it into the 
management of patients. 
 
Information on pharmacogenetics research within 
indigenous African populations are scarce.8 Ghana is 
one of the few countries in Africa in which substan-
tial genotype information is being accumulated, at 
least at the population level.2 Integrating this phar-
macogenetic information into both public health de-
cision-making and clinical practice still remains a 
goal all nations are aspiring to achieve.  
 
Recognizing the significant anticipated opportunities 
and challenges that pharmacogenetics will bring to 
healthcare was the catalyst for an Academic Affairs 
Committee of the American Association of Colleges 
of Pharmacy (AACP) report in 2002.9 The American 
College of Physicians (ACP) in 2005 also acknowl-
edged that it was increasingly important for physi-
cians to be knowledgeable about genetic testing and 
counseling. In 2006, the American Nurses Associa-
tion (ANA) established genetic competencies for 
nurses and recommended its use in nursing educa-
tion.10 The National Coalition for Health Professional 
Education in Genetics (NCHPEG) then established 
core competencies expected of all healthcare profes-
sionals with associations representing individual spe-
cialties also following suit.11  
 
It is therefore clear that inadequate education at un-
dergraduate and postgraduate levels will be a hin-
drance to the wide spread introduction of pharmaco-
genetics into patient management. A report published 
in 2005 shows that 40% of pharmacy schools sur-
veyed in the US did not have any instruction of 
Pharmacogenetics in their curriculum.12 In a second 
report, Pharmacogenetics was not taught in over 20% 
of the 41 responding US Pharmacy Schools.13 The 
academic members of the focus group of the 2008 
American Association of Pharmaceutical Scientist 
therefore expressed concern about the need for phar-
macogenetics teaching which have not been met and 
recommended that pharmacogenetics should be 
thought in Pharmacy schools.  
 
The International Society of Pharmacogenetics published 
a number of recommendations in 2005 to increase Phar-
macogenetics knowledge. This included the teaching of 
pharmacogenetics in undergraduate medical school.14  
 
A study among 34 medical schools in the UK after the 
recommendation of International Society of Pharmaco-
genetics on teaching of Pharmacogenetics in undergrad-
uate schools, showed that 19 (56%) of these schools re-
sponded to the questionnaires. A total of 84% (16 out of 
19) of schools that responded provided Pharmacogenet-
ics teaching.15 A recent study in the US also showed that 
92% (69 out of 75) colleges now include Pharmaco-
genetics in their Pharm D curriculum as compared to 
50% (16 out of 32) in 2005.16   
 
Despite the outstanding amount of evidence promoting 
pharmacogenetics education and practice in some devel-
oped countries, most countries in the developing world 
of which Ghana is an example seem to be lagging behind 
in pharmacogenetics education in their universities.  
 
The first objective of this survey is to assess the extent 
and depth of knowledge, perception and education of 
healthcare professionals in the area of pharmacogenetics 
in Ghana. The second objective is to determine the 
knowledge of pharmacogenetics among faculty members 
of healthcare training institutions in Ghana. 
 
METHODS 
This preliminary descriptive study was conducted in sev-
en health institutions in the Greater Accra region and 
four academic institutions between March and June 2013 
using Semi-structured questionnaires. The study was 
approved by Central University College Protocol Review 
Committee and consent was obtained from the respond-
ents with assurance of anonymity of their responses be-
fore questionnaires were administered. The first part of 
the study involved respondents from a teaching hospital 
(Korle bu Teaching Hospital), a regional hospital (Ridge 
Hospital), an urban hospital (Tema General Hospital) 
and 4 other private clinics within the Accra/Tema metro-
politan area. These seven health institutions were con-
veniently selected for the study as a fair representation of 
clinical practice in the region. The first set of 100 pre-
tested questionnaires was administered to a convenient 
sample of healthcare professionals mainly doctors, 
pharmacists and nurses practicing in these health institu-
tions.  
 
A second set of 40 questionnaires was used to interview 
faculty members of health training institutions known to 
be associated with programs where genetics, biochemis-
try and pharmacology content were covered.  
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These faculty members from the following health 
training institutions in Ghana were purposefully se-
lected and approached for the study. The training 
institutions were the School of Medicine and Dentis-
try Korle-bu (University of Ghana); School of Phar-
macy (University of Ghana); School of Medicine of 
Medical Sciences at Kwame Nkrumah University of 
Science and Technology (KNUST) Kumasi; School 
of Pharmacy (KNUST); and the School of Applied 
Sciences at Central University College (CUC) train-
ing Pharmacist and Physician Assistants. The ques-
tions used in this study were modeled on findings 
from previous literature regarding the incorporation 
of pharmacogenetics into clinical practice and a pre-
vious study by Latif and Mckay.13  
 
Statistical Analysis 
All data were entered into Statistical Package for 
Social Science (ver.17.0; SPSS, Chicago, IL) and 
imported into StataTM version 10 (StataCorp, College 
Station, Texas, United States) for statistical analyses. 
Data were summarized as frequencies and proportions. 
 
RESULTS 
Ninety of the 100 (90%) healthcare professionals con-
tacted completed and returned the questionnaires. Forty-
two (46.7%) of these healthcare professionals were doc-
tors, 29 (32.2%) were pharmacists and 19 (21.1%) were 
nurses practicing at selected hospitals and clinics within 
the Accra/Tema metropolitan area.  Of these 90 respond-
ents, 49 (54%) were male and 41 (46%) were female. 
Thirty four (38%) of these responding professionals, had 
below 5 years of practice experience, 34 (38%) had 
5years to 10 years practice experience and 22 (24%) had 
been practicing for over 10 years. Majority of the 
healthcare professionals have heard the word pharmaco-
genetics from varied sources (Table 1).  
 
 
Table 1 Source of pharmacogenetics information 














Medical doctor 0 (0) 16 (38.1) 12 (28.6) 1 (2.4) 1 (2.4) 12 (28.6) 0 (0) 
Pharmacist  1 (3.5)  6(20.7)  12 (41.4) 0 (0)  3 (10.3)  7 (24.1)  0 (0) 
Medical Nurse 3 (15.8) 9 (47.4) 3 (15.8) 0 (0) 2 (10.5) 1  (5.3) 1 (5.3) 
  
 











Medical doctor 1 (2.4) 5 (11.9) 32 (76.2) 4 (9.5) 0 (0) 
Pharmacist* 0 (0) 5 (17.9) 11 (39.3) 9 (32.1) 3 (10.7) 
Nurse 0 (0) 0 (0) 10 (52.6) 6 (31.6) 3 (15.8) 
* No response from 1 pharmacist 
 
Table 2 shows the respondents’ rating of their 
knowledge of pharmacogenetics as excellent, very 
good, good, poor, or very poor. All the respondents 
except one pharmacist answered this question.  
 
All the doctors and pharmacists interviewed taught 
pharmacogenetics was relevant to their individual pro-
fessions especially in the areas of diagnosis and treat-
ment. Nine (47.4%) of nurses however, do not think 
pharmacogenetics was relevant to their profession and 
two of these nurses do not think pharmacogenetics 
should be part diagnosis and treatment. All respond-
ents, except one doctor and one pharmacist, said phar-
macogenetics should be part of their continuous profes-




Table 3 Relevance of knowledge of pharmacogenetics 
Is pharmacogenetics relevant to your profes-
sion? 




Medical doctor 0 (0) 42 (100) 
Pharmacist 0 (0)  29 (100) 
Nurse 9 (47.4) 10 (52.6) 
Should pharmacogenetics be part of diagnosis 
and treatment? 
Medical doctor 0 (0) 42 (100) 
Pharmacist  0 (0)  29 (100) 
Nurse 2 (10.5) 17 (89.5) 
Should pharmacogenetics information be in-
cluded in your continuing professional devel-
opment training? 
Medical doctor 1 (2.4) 41 (97.6) 
Pharmacist  0 (0)  29 (100) 
Nurse 1 (5.3) 18 (94.7) 
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Table 4 provides a summary of the opinions of health 
professionals surveyed. Nine (21.4%) doctors, 10 
(34.5) pharmacist and 10 (52.6) nurses were not sure if 
pharmacogenetic testing will help decrease the number 
of Adverse Drug Reactions (ADRs). 
 
Table 4 Summary of knowledge of pharmacogenetics 












How important is phar-
macogenetics for identifi-
cation of drug targets 
0 (0) 6 (18.8) 10 (31.23) 16 (50) 
How important is phar-
macogenetics for reducing 
cost of treatment 
2 (6.3) 7 (21.9) 11 (34.4) 12 (37.5) 
How important is phar-
macogenetics for under-
standing drug action  
1 (3.1) 4 (12.5) 9 (28.1) 18 (56.3) 
How important is phar-
macogenetics for reducing 
ADRs 
0 (0) 4 (12.5) 8 (25) 20 (62.5) 
How important is phar-
macogenetics for improv-
ing efficacy 
0 (0) 8 (25) 5 (15.6) 19 (59.4) 
 
The second objective of this survey was to assess the 
knowledge of pharmacogenetics among faculty mem-
bers of selected Health training institutions. Thirty-two 
(80%) out of the 40 questionnaires administered to 
faculty members of Health Training Institutions were 
completed and returned. Eight (25%) these faculty 
members train only medical doctors, 18 (56.2%) train 
only pharmacists and 6 (18.8%) train both pharmacists 
and medical doctors.  
 
Fifteen 17 (53.1%) respondents indicated their field of 
expertise as being related to pharmacology or biology 
with the 15 (46.9%) indicating their field of expertise 
as non-Pharmacology or Biology.  
 
Nineteen (59.4%) out of the 32 respondents have heard 
of pharmacogenetics which correlates with the number 
of respondents that said their field of expertise is relat-
ed to pharmacology. The respondents rated their 
knowledge of pharmacogenetics as either excellent (2, 
6.3%), very good (3, 9.4%), good (9, 28.1%), poor (12, 
37.5%), and very poor (6, 18.8%). 
 
Faculty members believe that pharmacogenetics is im-
portant for the identification of new drug targets, re-
ducing overall cost of treatment, gaining a better un-
derstanding of the mechanisms of action of drug treat-
ments, prevention of adverse drug reactions and im-
proving efficacy of medicine (Table 5). 
 
Table 5 Importance of pharmacogenetics 
Is the knowledge of pharmacogenetics likely to decrease the number of 
ADRs? 








Medical doctor 1 (2.4) 9 (21.4) 19 (45.2) 13 (31.0) 
Pharmacist 0 (0) 10 (34.5)  10 (34.5)  9 (31.0) 
Nurse 0 (0) 10 (52.6) 8 (42.1) 1 (5.3) 
Is the knowledge of pharmacogenetics likely to decrease the cost of develop-
ing drugs? 
Medical doctor 7 (16.7) 17 (40.5) 13 (31.0) 5 (11.9) 
Pharmacist  5 (17.2) 13 (44.8)  6 (20.7)  5 (17.2) 
Nurse 4 (21.1) 12 (63.2) 3 (15.8) 0 (0) 
 
Table 6 provides the summary of relevant pharmaco-
genetics teaching-related items.  Of the 32 members of 
faculty that responded, 7 (21.9%) said pharmacogenet-
ics was not part of the curriculum, 13 (40.6%) did not 
know if pharmacogenetics was part of their institu-
tions’ curriculum. Only 12 (37.5%) said it was part of 
their curriculum.  
 
The authors independently verified that School of Med-
icine and Dentistry (UG), School of Pharmacy (UG) 
and School of Pharmacy (KNUST) have pharmaco-
genetics as part of their curriculum. School of Applied 
Sciences (CUC) does not have pharmacogenetics as 













Does syllabus contain genetic information? 19 (59.4) 7 (21.9) 6 (18.8) 
Does syllabus contain pharmacogenetics infor-
mation? 
12 (37.5) 7 (21.9) 13 (40.6) 
Should students be equipped with pharmaco-
genetics information? 
31 (96.9) 1 (3.1) 0 (0) 
Would you like to know more about pharmaco-
genetics? 
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All faculty members agreed that students should be 
equipped with knowledge of pharmacogenetics. Major-
ity of the Faculty members said dissemination of 
knowledge of pharmacogenetics can be done through 
lectures and a few said through seminars. Twenty sev-
en (84.4%) respondents taught including pharmaco-
genetics in the curriculum was a better mode of equip-
ping students with that knowledge as compared to sem-
inars (2, 6.3%). Three faculty members did not re-
sponse to this question. Twelve (38%) of faculty mem-
bers taught  that less than 4 hours of pharmacogenetics 
education was enough to equip the students while 10 
(31.3%) taught  4 hours to 8 hours was  adequate, 5 
(15.6%) taught it should be more than 8 hours  and  5 
(15.6%)  faculty did not give a response to this ques-
tion. Majority of faculty members (96.9%) said they 
would be interested in gaining more knowledge on 
pharmacogenetics.   
 
DISCUSSION 
Pharmacogenetics has delivered an impressive amount 
of information in the past 50 years; however, it has 
suffered from lack of integration into clinical practice. 
Over the past decade, pharmacogenetics has evolved 
into an essential tool to ensure optimal medication use 
for a growing number of medications and disease 
states. It has become important that present day health 
professionals (Doctors, Pharmacist, Physician  Assis-
tants and Nurses) are equipped to use pharmacogenet-
ics information to appropriately individualize medica-
tion therapy for patients now and in the near future.17  
 
Pharmacogenetics training in health professional insti-
tutions, however, appears to be lagging behind despite 
the rapid advances in research. Insufficient education 
of health professionals and the lack of adequate patient 
education have been observed as major barriers to 
pharmacogenetics being integrated into clinical prac-
tice.15  
 
This descriptive survey assessed knowledge of phar-
macogenetics among health professionals and faculty 
members of health training institutions. The survey 
showed that majority of the professionals interviewed 
have heard about pharmacogenetics and view it as clin-
ically relevant to their various areas of practice. Nine 
(50%) of nurses however, do not think pharmacogenet-
ics was relevant to their profession and two of these 
nurses do not think pharmacogenetics should be part of 
diagnosis and treatment.  
 
Many of the professionals have gained their knowledge 
of pharmacogenetics mainly from their colleagues and 
the internet. It appears the pharmacogenetics infor-
mation gained by these professionals were from self-
directed learning which is beneficial but may result in 
contrasting levels of knowledge of pharmacogenetics 
and may lead to unequal standards of practice among 
these professionals. It was however encouraging to 
note that health professionals between the age range of 
25years to  29 years with the least years of practice 
experience, seemed  to form  the majority of the re-
sponding professionals who have heard of pharmaco-
genetics.  
 
In 2004, International Society of Pharmacogenomics 
(ISP) meeting in Greece focused on incorporation of 
pharmacogenomics into the medical schools core cur-
ricula. The participants and members of the ISP Phar-
macogenomics Education Forum agreed on ‘Recom-
mendations and Call for Action’ to Deans of Education 
at Medical, Pharmaceutical, and Health Schools global-
ly. The call was on Deans of Education to incorporate 
pharmacogenomics in the core teaching curricula of 
pharmacology without further delay.14  
 
The National Coalition for Health Professional Educa-
tion in Genetics (NCHPEG) in the USA has also made 
recommendations on "Core Competencies in Genetics 
Essential for All Health-Care Professionals".11 In 
2006, the American Nurses Association (ANA) estab-
lished genetic competencies for nurses and recom-
mended its use in nursing education 10 and in 2007, the 
American Council on Pharmacy Accreditation set 
Pharmacogenetics as a required component of the 
pharmacy curriculum.9  
 
Schools of Medicine and Pharmacy in the developed 
world are working to address the educational needs of 
their students to ensure that they are adequately pre-
pared for pharmacogenetics challenges. Most schools 
of pharmacy now include pharmacogenetics content in 
their curriculum.16 Most US and Canadian medical 
schools have begun to incorporate pharmacogenetics 
material into their curriculum although the extent of 
instruction is less in Canada than it is in US pharmacy 
schools.18  
 
There are very few reports of pharmacogenetics teach-
ing around the world reported in literature.13,15,16 These 
reports are almost absent from institutions in low and 
middle-income countries. There is an existing gap be-
tween research and practice, efforts should be made to 
narrow this gap. It was observed during this study that 
some Schools of Medicine and Pharmacy in Ghana 
have introduced the teaching of pharmacogenetics as 
part of their pharmacology curriculum. The schools 
without pharmacogenetics as part of their curriculum 
should be encouraged to initiate it into the education of 
their healthcare professionals. 
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A recent study on perceptions of healthcare profession-
als towards pharmacogenetics in Nigeria concluded 
that Pharmacist and Pharmacologists were aware of the 
benefits of Pharmacogenetics. However, many cited 
hurdles that needed to be overcome for pharmacogenet-
ics to become routine part of patient care.19 This study 
also showed that Healthcare professionals were 
aware of the significance of pharmacogenetics in pre-
vention and management of adverse drug reactions.  
However, majority were unsure of its potential benefits 
to drug discovery and its role in the reduction of cost of 
healthcare. Clinical application of evidence-based 
pharmacogenetics information has the potential to help 
healthcare professionals provide safe and effective 
medication management to patients. However, there is 
a gap between the advances of pharmacogenetics dis-
covery and the health professionals' knowledge regard-
ing pharmacogenetics testing and therapeutic uses.  
 
Teaching current health professionals in schools and 
continuously updating the knowledge of pharmaco-
genetics of those already in practice should not be 
postponed until a new paradigm arrives. Healthcare 
professional bodies should therefore endeavor to edu-
cate their members on pharmacogenetics through con-
tinuous professional development programmes so as to 
prepare them for the future. Such measures would as-
sist in the development of competency standards for 
the health professionals for the future incorporation of 
pharmacogenetics into the healthcare system.  
 
 Many of the healthcare professionals interviewed were 
of the opinion that including pharmacogenetics into the 
curriculum of undergraduate students in health training 
institutions would provide an opportunity for these 
students to acquire knowledge and gain a better under-
standing of this field before passing out of school. 
General consensus among clinical pharmacology edu-
cators was that pharmacogenetics should be included in 
current medical school training. Based on the ISP rec-
ommendations for undergraduate medical teaching of 
pharmacogenetics, most British medical schools now 
teach pharmacogenetics for 1–2 hours.15 Data from this 
survey suggests 4 hours to 8 hours of teaching phar-
macogenetics be incorporated into the curricula of 
medical and pharmacy schools in Ghana. This can be 
done at the stage when the students are already familiar 
with basic principles of pharmacokinetics, pharmaco-
dynamics and have completed their basic training in 
human genetics. Pharmacogenetics can also be taught 
as an elective semester-long graduate programme for 
postgraduate students. Health training institutions need 
to assist their faculty members to develop the requisite 
skill and knowledge to present pharmacogenetics in-
formation to students.  
Collaborative programmes with other educational insti-
tutions that have the expertise in the area can be the 
starting point. 
 
Health training institutions may start by introducing 
their students to core areas such as definition of phar-
macogenetics, aims of pharmacogenetics, clinical ex-
amples of pharmacogenetics, potential advantages and 
disadvantages of pharmacogenetics and the future of 
pharmacogenetics. The mode of instruction may be 
lectures for undergraduate students, seminars and case-
led for post graduate and practicing professionals. 
 
Clinical Pharmacogenetics Implementation Consortium 
(CPIC) formed in 2009 with an ultimate goal of guid-
ing clinicians to make patient care decisions for specif-
ic drugs when genetic results are available. CPIC has 
been providing a comprehensive review of the existing 
literature on targeted pharmacogenetic examples and 
providing guidelines authored by experts in the field on 
the clinical use of pharmacogenetic information. CPIC 
has focused on available pharmacogenetic data and 
how the clinician can use this genetic information to 
guide drug therapy. More than fifteen CPIC guidelines 
have been published and these include TPMT and thio-
purines, CYP2C19 and clopidogrel, VKORC1/CYP2C9 
and warfarin, CYP2D6 and codeine, HLA-B and ab-
acavir, SLCO1B1 and simvastatin, HLA-B and allopu-
rinol, and CYP2D6/CYP2C19 and tricyclic antidepres-
sants20  which can be used as teaching matarial in 
schools and for CPD seminars. 
 
Introducing pharmacogenetics teaching will have an 
effect on other areas of the school curriculum; howev-
er, there is the need to find that balance to give our 
healthcare professionals the opportunity to compete on 
the world stage. A number of studies have been done in 
Ghana over the years in the area of pharmacogenetics.2 
It is about time to start introducing students to phar-




These findings provide baseline information on the 
knowledge of pharmacogenetics among practicing 
health professionals and faculty members of the Health 
training institutions. Some of these professionals are 
aware of the emerging field of pharmacogenetics and 
taught it was relevant to their individual professions 
especially in the areas of diagnosis and treatment. A 
few health training institutions have introduced phar-
macogenetics into their curriculum but many are yet to 
do so. There is the need for continuous professional 
development education in pharmacogenetics to even 
out the knowledge base of all healthcare professionals. 
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Study limitations 
One limitation of our study is that practicing 
Healthcare professionals were selected from hospitals 
and private clinics in only Accra/Tema metropolitan 
area of Greater Accra region of Ghana. This may not 
be representative of all healthcare professionals in 
Ghana. Faculty members of the newly establish health 
training institutions were not part of this study. In spite 
of these limitations, this study provides the first 
glimpse of knowledge pharmacogenetics in Ghana. 
 
ACKNOWLEDGEMENT 
The authors would like to express their appreciation to 
Mr Edmund Nartey of School of Medicine and Dentis-
try for statistical analysis of the data.  
 
REFERENCES 
1. Webster A, Martin P, Lewis G, Smart A. Integrat-
ing pharmacogenetics into society: in search of a 
model. Nat Rev Genet 2004;5(9):663-9. 
2. Kudzi W, Adjei GO, Ofori-Adjei D, Dodoo AN. 
Pharmacogenetics in Ghana: reviewing the evi-
dence. Ghana Med J 2011;45(2):73-80. 
3. Pirmohamed M. Pharmacogenetics and phar-
macogenomics. Br J Clin Pharmacol 
2001;52(4):345-7. 
4. Giacomini KM, Brett CM, Altman RB, et al. The 
pharmacogenetics research network: from SNP 
discovery to clinical drug response. Clin Pharma-
col Ther 2007;81(3):328-45. 
5. Lesko LJ. Personalized medicine: elusive dream or 
imminent reality? Clin Pharmacol Ther 
2007;81(6):807-16. 
6. Pang GS, Wang J, Wang Z, Lee CG. Predicting 
potentially functional SNPs in drug-response 
genes. Pharmacogenomics 2009;10(4):639-53. 
7. Frueh FW, Amur S, Mummaneni P, et al. Phar-
macogenomic biomarker information in drug la-
bels approved by the United States food and drug 
administration: prevalence of related drug use. 
Pharmacotherapy 2008;28(8):992-8. 
8. Marsh S. Pharmacogenetics: global clinical mark-
ers. Pharmacogenomics 2008;9(4):371-3. 
9. Johnson JA BJ, Evans WE, et al. Pharmacogenet-
ics. A scientific revolution in pharmaceutical sci-
ences and pharmacy practice. Report of the 2001 -
2002 Academic Affairs Committee. . Am J Pharm 
Educ 2002;66:12S-17S. 
10. Jenkins J, Calzone KA. Establishing the essential 
nursing competencies for genetics and genomics. J 
Nurs Scholarsh 2007;39(1):10-6. 
11. Recommendations of core competencies in genet-
ics essential for all health professionals. Genet 
Med 2001;3(2):155-9. 
12. Moridani M. The Significance of Phar-
macogenomics in Pharmacy Education and Prac-
tice American Journal of Pharmaceutical Educa-
tion 2005;69 (2) Article 37. 
13. Latif DA. Pharmacogenetics and phar-
macogenomics instruction in schools of pharmacy 
in the USA: is it adequate? Pharmacogenomics 
2005;6(4):317-9. 
14. Gurwitz D, Lunshof JE, Dedoussis G, et al. Phar-
macogenomics education: International Society of 
Pharmacogenomics recommendations for medical, 
pharmaceutical, and health schools deans of educa-
tion. Pharmacogenomics J 2005;5(4):221-5. 
15. Higgs JE, Andrews J, Gurwitz D, Payne K, New-
man W. Pharmacogenetics education in British 
medical schools. Genomic Med 2008;2(3-4):101-5. 
16. Murphy JE, Green JS, Adams LA, Squire RB, Kuo 
GM, McKay A. Pharmacogenomics in the curricu-
la of colleges and schools of pharmacy in the 
United States. Am J Pharm Educ 2010;74(1):7. 
17. Roederer MW, Sanchez-Giron F, Kalideen K, 
Kudzi W, McLeod HL, Zhang W. Pharmacogenet-
ics and rational drug use around the world. Phar-
macogenomics 2011;12(6):897-905. 
18. Green JS, O'Brien TJ, Chiappinelli VA, Harralson 
AF. Pharmacogenomics instruction in US and Ca-
nadian medical schools: implications for personal-
ized medicine. Pharmacogenomics    2010;11(9): 
1331-40. 
19. Madadi P. EE, Babatunde EO. Perceptions of 
health care professionals towards pharmacogenet-
ics in Nigeria: Preliminary Results. West African 
Journal of Pharmacy 2011;1:97 - 101. ✪ 
 
 
 
